Update on the Management of Diabetic Macular Edema

Shawn M Ivenson1 and W Lloyd Clark1,2

1. Palmetto Health - University of South Carolina Medical Group, Columbia, South Carolina, US; 2. Assistant Clinical Professor of Ophthalmology, University of South Carolina School of Medicine, Palmetto Retina Center LLC, West Columbia, South Carolina, US

Diabetic macular edema (DME) is a treatable sequela of diabetic retinopathy and a significant cause of visual morbidity among working age individuals worldwide. While anti-vascular endothelial growth factor (anti-VEGF) agents are first-line agents in the management of DME, corticosteroids and laser therapy can play a role as well. Despite a growing understanding of best clinical practices, many patients respond unpredictably to therapy. This article will briefly review current treatment modalities and discuss future treatment options for managing DME.

Keywords
Diabetic macular edema, anti-vascular endothelial growth factor, VEGF; macular laser, aflibercept, bevacizumab, ranibizumab

Disclosure: Shawn M Ivenson has nothing to disclose in relation to this article. W Lloyd Clark has received consulting fees from Bayer, Genentech/Roche, Regeneron; speakers bureau from Genentech/Roche, Regeneron; contracted research: Allegan, Inc., Genentech/Roche, Regeneron; and equity from VERSYL, Inc. No funding was received in the publication of this article. This study involves a review of the literature and did not involve any studies with human or animal subjects performed by any of the authors.

Authorship: All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published.

Open Access: This article is published under the Creative Commons Attribution Noncommercial License, which permits any noncommercial use, distribution, adaptation, and reproduction provided the original author(s) and source are given appropriate credit.

Received: January 10, 2017
Accepted: February 15, 2017
Citation: US Ophthalmic Review; 2017;10(1):52–6
Corresponding Author: Lloyd Clark, MD, Palmetto Retina Center, 124 Sunset Court, West Columbia, SC 29169, US. E: LClark@PalmettoRetina.com

Diabetic retinopathy is the leading cause of blindness worldwide among patients aged 20–74. Among eyes with diabetic retinopathy, diabetic macular edema (DME) accounts for a significant proportion of vision loss and associated morbidity, and the reported incidence is quite high, occurring in 26.1% of type 1 diabetics according to The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Tight glucose control significantly reduces the risk of development and progression of diabetic retinopathy in both type 1 and type 2 diabetics, and this remains the best preventative measure. These studies have additionally shown other modifiable risk factors, such as hypertension control, play important roles in managing diabetic eye disease. For those eyes that do develop macular edema, a number of treatment options exist, and research into new and modified modalities is ongoing. Recently, first-line therapy for DME has shifted and patients and clinicians can expect visual improvement with consistent treatment. As research advances, it is likely that new therapies will emerge and preferred practice patterns will continue to evolve.

Anti-vascular endothelial growth factor Background

Anti-vascular Endothelial Growth Factor (anti-VEGF) agents have become standard of care in the treatment of center-involving DME. The first anti-VEGF agent used in treating DME was pegaptanib (Macugen®, Pfizer, New York, US), a pegylated anti-VEGF aptamer. In the early 2000s, a phase II study was completed showing pegaptanib reduces macular thickness and improves vision, however, the development of this agent did not move forward as more efficacious anti-VEGF agents came to market. Today, clinicians choose from three commercially available anti-VEGF agents for treating DME and for treating diabetic retinopathy associated with DME; bevacizumab (Avastin®, Genentech, California, US), ranibizumab (Lucentis®, Genentech, California, US), and aflibercept (Eylea®, Regeneron, New York, US), the latter two of which have Food and Drug Administration (FDA) approval.

Bevacizumab, ranibizumab, and aflibercept are all anti-VEGF medications, however there are notable structural differences between these agents. Bevacizumab is a recombinant, humanized, full length monoclonal antibody to VEGF. Ranibizumab is a monoclonal antibody antigen-binding fragment to VEGF. Ranibizumab is unique in that it lacks an Fc portion, which results in a more rapid clearance from the body, a characteristic some believe plays a role in differences in systemic adverse effects, although this is not conclusively proven. Aflibercept is a recombinant fusion protein consisting of binding domains to VEGF-receptors 1 and 2 bound to the Fc portion human immunoglobulin G1 (IgG1). These structural differences affect binding affinity for VEGF, which plays a role in differences in vivo activity and clinical response. Analyzing binding affinity is highly complex and has been studied with mixed results. While aflibercept is thought to be more potent, a recent study by
Yang et al., found that both aflibercept and ranibizumab, under uniform conditions, are equipotent in their ability to inhibit VEGF, and both had significantly greater binding affinity compared to bevacizumab. Nevertheless, all three agents significantly reduce intraocular VEGF levels.

Efficacy
There is extensive literature reporting clinical outcomes using bevacizumab, ranibizumab and aflibercept; however, most of the controlled clinical trials have been performed using ranibizumab or aflibercept. Although a detailed review of the many anti-VEGF studies is beyond the scope of this article, the Diabetic Retinopathy Clinical Research Network (DRCR.net) Protocol T is worth mentioning as a sentinel study that prospectively compared all three agents for treating DME in a randomized clinical trial. The primary endpoint for Protocol T was the statistical change in visual acuity at 1-year, and this study reported all medications improved vision and decreased macular thickness. However, at worse levels of baseline vision (i.e., ≤ 20/50), the aflibercept group obtained a statistically significant improvement in visual acuity letter score compared to the other agents. Two-year outcomes have since been published showing the visual acuity improvement (12.8, 10.0, and 12.3 letters) and number of injections (15, 16, 15) over 2 years was similar between the aflibercept, bevacizumab and ranibizumab groups, respectively. Visual acuity improvements were greater among eyes with baseline visual acuity ≤ 20/50, 18.1, 13.3, and 16.1 letters, respectively, with aflibercept remaining superior to bevacizumab (p=0.02), however the statistical superiority over ranibizumab that was observed in 1 year data was no longer observed (p=0.18). Protocol T also showed a significant reduction in central subfield thickness (CST) among all three agents at 2-years, with the greatest reduction in the aflibercept group (-211±155), followed by ranibizumab (-185±158) and bevacizumab (-174±159) groups. While Protocol T was a well designed, large, randomized, prospective study, all studies have limitations. The main limitations of Protocol T include the drugs not being used according to their labeled dosing strategy and that this is a single trial rather than parallel trials required for FDA registration. An additional study of similar nature would be of great benefit to confirm Protocol T’s findings, but to date no study has been organized. There are additional anti-VEGF studies evaluating these agents in various scenarios, and all three medications continue to represent reasonable choices.

Safety
Anti-VEGF agents have a remarkable safety profile and have been administered in tens of thousands of eyes with DME and other conditions such as age-related macular degeneration, retinal vein occlusions, and to a lesser degree in conditions such as juxtapfoveal macular telangiectasia, central serous chorioretinopathy, and retinopathy of prematurity. Serious adverse events are relatively uncommon and include: sterile intraocular inflammation, rhegmatogenous retinal detachment, sustained intraocular pressure (IOP) elevation, ocular hemorrhage, endophthalmitis, and various systemic events. All anti-VEGF agents have been associated with detectable levels in the systemic circulation; however, systemic event rates vary by trial and by anti-VEGF agent. The DRCR.net Protocol T reported the rates of Anti-platelet Trials’ Collaboration (APT) events, and found they occurred in 5% with aflibercept, 8% with bevacizumab and 12% with ranibizumab, with a statistically significant increased rate in ranibizumab versus aflibercept (p=0.047), but not between the other groups. It is unclear if this increased APTC rate in ranibizumab eyes was a chance finding since it has not been observed in other protocols.

There are other adverse events that have been reported specifically in patients with diabetic retinopathy, all of which are quite rare. Multiple groups have reported progression of tractional retinal detachment in advanced proliferative diabetic retinopathy (PDR) eyes, and ghost cell glaucoma when bevacizumab was used as an adjunct to vitrectomy in PDR.

Safety

Selecting an anti-VEGF agent
What we have learned from Protocol T is, from a clinical standpoint, there is no single agent that is vastly superior to others, and all three agents represent reasonable options for treating DME. Cost, baseline visual acuity, medication availability, shelf life, and yet to be determined factors will continue to play roles in selecting an agent. The American Society of Retinal Specialist convened a group of experts to provide their perspective on the clinical findings of Protocol T and stated that all three agents result in improved vision, and “many specialists might initiate therapy with bevacizumab when visual acuity is good (i.e., 20/32 to 20/40 as measured in the DRCR Network), recognizing that the cost-effectiveness of bevacizumab outweighs that of aflibercept or ranibizumab”.

Data from Protocol T do suggest aflibercept is a more efficacious anti-VEGF medication among eyes with worse baseline visual acuity (i.e., ≤ 20/50). Additionally, it should be noted that the value of more rapid early visual acuity and anatomic improvements on long-term outcomes is not yet completely understand, and it is possible that 5- and 10-year studies will show greater discordance in visual acuity outcomes between anti-VEGF medications. Furthermore, certain patient factors, such as inability to return to clinic regularly or systemic comorbidities such as recent vascular events, may be relative contraindications to anti-VEGF therapy and altogether persuade clinicians into using a non-anti-VEGF treatment modality.

Corticosteroid agents
Background
VEGF certainly plays a major role in the etiology of DME; however, other factors are at play. The pathogenesis of DME includes breakdown of the blood-retinal barrier and an increase in the concentration of numerous cytokines and other inflammatory mediators. Corticosteroids do affect VEGF levels, but additionally are potent modulators of these other inflammatory mediators, and as such, can be used to treat DME. Corticosteroids initially gained popularity when outcomes with laser were suboptimal and the first report of intravitreal crystalline corticosteroid injection for the treatment of DME was published in 2001. There are now three fluorinated synthetic corticosteroids that lack mineralocorticoid activity used in clinical practice. Dexamethasone as a sustained release biodegradable implant (DEX implant; Ozurdex®, Allergan Inc., California,
US OPHTHALMIC REVIEW

07/04/2017   14:12

Clark_FINAL.indd   54

Review Retina

Over the years, several studies have been conducted to investigate the utility of corticosteroids for the treatment of DME. The DRCR.net Protocol B found at 2 years, treatment with focal/grid photocoagulation was more effective and had fewer adverse effects than 1 mg or 4 mg doses of intravitreal triamcinolone acetonide.25 The DRCR.net Protocol E randomized patients to laser and or subTenon’s triamcinolone and found no additional benefit to subTenon’s steroid.26 In a randomized, double-masked, placebo-controlled trial, Gillies et al. reported, at 2 years, intravitreal triamcinolone improved vision and reduced macular thickness in eyes with DME refractory to macular laser.27 Following this, DRCR.net Protocol I evaluated both intravitreal triamcinolone acetonide and ranibizumab in combination with early and deferred macular photocoagulation, and found that at 2 years, the steroid group outcomes were substantially inferior to the intravitreal ranibizumab with or without photocoagulation or photocoagulation alone groups.28 Subanalysis of Protocol I data limited to eyes that were pseudophakic at baseline did show similar improvements in visual acuity compared to the ranibizumab arm, however the steroid arm had an increased rate of IOP elevation. Ozurdex typically has a duration of effect between 3–6 months, and the MEAD Study Group has shown with 4–5 injections over a 3-year period, a significant proportion of patients had greater than 100 micron reduction in macular thickness and an associated 5.9 and 6.5 letter gain in the 0.35 mg and 0.7 mg dosing groups, respectively.29 Similarly, the Iluvian implant (Alimera Sciences, Inc., Georgia, US) has been shown to be effective; however, this nonbiodegradable implant has been shown to elute drug for up to 3 years.30 Both implants result in cataract formation in a significant number of phakic patients and this finding confounds visual acuity outcomes. When adjusting for cataract formation, intravitreal steroids (via simple injection or sustained release implant) have been shown to have similar visual acuity efficacy as anti-VEGF agents.31,32

Safety

It is well known that corticosteroids accelerate cataract formation. DRCR.net Protocol B found the cumulative probability of cataract surgery at 3 years was 46% and 83% in the 1 and 4 mg steroid groups, both notably higher than the 31% in the laser group.23 The Ozurdex MEAD Study Group reported cataracts in 67.9%, 64.1%, and 20.4% of the 0.7 mg, 0.35 mg and sham eyes at 3 years, respectively.33 The FAME Study Group found almost all phakic eyes developed cataracts by 3 years follow-up, with rates of 81.7%, 88.7%, 50.7% in the low-dose, high-dose and sham groups, respectively.34 There are also a significant risk of IOP response with steroid use and a recent meta-analysis looking at ocular hypertension following intravitreal administration found 11–79% of eyes develop pressure elevation depending on the agent and dose used.40 One study found roughly one-third of eyes receiving the dexamethasone implant (27.7% in the high-dose and 24.8% in the low-dose) had an IOP increase ≥10 mmHg from baseline.35 Similarly, the fluocinolone implant is associated with high rates of IOP elevations, with rates of 37.1%, 45.5%, and 11.9% in the low-dose, high-dose and sham groups, respectively.36 Despite this significant incidence of IOP response, most eyes can be controlled medically. Among studies specifically for diabetic macular edema and following patients for at least 2 years, incisional glaucoma surgery rates have been reported to be between 0–8%.36–39

Selecting an agent

There are a number of corticosteroid agents and administration methods for treating DME and all have advantages and disadvantages. Topical corticosteroids are not typically used to treat DME as they do not readily reach therapeutic concentrations in the posterior segment; however, this route may allow for identification of IOP responders. SubTenon’s injections result in reasonable posterior segment concentrations and allow for identification of IOP response, but evidence suggests this route is not as effective as intravitreal injection. Intravitreal injections are done with triamcinolone acetonide or via implantation of a sustained release device.

Today, our recommended approach for patients with suboptimal anti-VEGF response or those with unacceptable treatment burden would be to use triamcinolone (Triesence®, Alcon, Texas, US) or Ozurdex to look for treatment and steroid response, and if favorable, consider Iluvien. We additionally advise clinicians counsel phakic patients on the high likelihood developing a visually significant cataract which may require surgery.

Macular laser treatment

Background

Macular grid and focal laser photocoagulation have been used for decades and this became the standard treatment for clinically significant DME after results of the Early Treatment Diabetic Retinopathy Study (ETDRS) were published in the late 1980’s.41 A number of laser platforms are available, all of which ultimately result in the laser-tissue interaction termed photocoagulation. This results in closure of leaking microaneurysms and in theory decrease oxygen demand through destruction of oxygen-consuming photoreceptors. Laser systems have evolved and now include lasers of different wavelengths, micropulsed lasers and navigable lasers, each of which has certain advantages. Many laser systems generate a single wavelength, however systems are available that allow selection from multiple color options. Some clinicians prefer yellow lasers because yellow light seems to be more selective for retinovascular lesions and may produce less scar formation; however, no large studies have proven differences between wavelengths affects clinical outcomes. Micropulsed lasers reduce heat transfer compared to a continuous wave, resulting in less tissue destruction and treatment without a visibly identifiable burn. Navigable lasers employ eye tracking and angiography-guidance software that improve accuracy and speed of treatment; however, cost continues to limited adoption of this technology.

Efficacy

A number of clinical trails have evaluated the outcomes of focal and or grid photocoagulation for the treatment of DME. The ETDRS was a sentinel study that evaluated both focal and early scatter photocoagulation for treating DME.42 This study found focal macular laser halved the rate of moderate vision loss (three or more lines) and increased the chance of moderate vision gain and reduced retinal thickening compared to a control group of untreated eyes. The ETDRS and other studies showed macular laser is effective in reducing vision loss; however, the introduction of anti-
Combination treatments and future treatment options

The current consensus first-line treatment for vision loss due to DME is intravitreal injection of an anti-VEGF agent. Treatment with these drugs results in a rapid reduction in macular thickness and often results in significant visual acuity improvement. Despite anti-VEGF’s favorable safety and efficacy profile, there are still several downsides, notably high treatment cost and visit burden. While several studies have found a decreased dependence on injections over time, patients still require fairly frequent follow-up, as reaccumulation of retinal fluid is not uncommon when injections are stopped. A number of ongoing studies are looking at new agents and combination therapies to evaluate the optimal regimen for visual and anatomical outcomes while limiting the frequency of treatments.

The DRCR network continues to actively investigate DME treatments through many study protocols. Protocol U (ClinicalTrials.gov Identifier: NCT01945866) is currently in phase II and was designed to evaluate visual acuity and retinal thickness outcomes in eyes receiving an intravitreal dexamethasone implant plus anti-VEGF versus sham plus anti-VEGF. Corticosteroid and anti-VEGF combination may have a synergistic effect by dramatically reducing levels of VEGF, cytokines and other inflammatory mediators. Protocol V (ClinicalTrials.gov Identifier: NCT01909791) is currently recruiting participants to investigate prompt anti-VEGF versus prompt laser plus deferred anti-VEGF versus observation plus deferred anti-VEGF among eyes with good vision (≥ 20/25), with no or minimal prior treatment for DME. Protocol W (ClinicalTrials.gov Identifier: NCT02634333) is looking at patients without center involving DME but with severe non-PDR (NPDR) to determine the safety and efficacy of prompt anti-VEGF versus observation for prevention of vision-threatening outcomes. Similarly, Panorama (ClinicalTrials.gov Identifier NCT02718326) is a study, currently in phase III, comparing anti-VEGF ( aflibercept) versus sham in patients with moderately severe to severe NPDR to determine the effect on retinopathy, vision and the development of DME.

Newer anti-VEGF agents are being developed that display higher potency for binding VEGF. Given the relatively high affinity of some currently available agents, it remains to be seen whether targeting these additional proteins will offer any improved or prolonged efficacy over currently available agents. In addition to new anti-VEGF molecules, other molecules that can retard vascular growth and leakage are also being investigated. Anti-angiopoietin is currently being evaluated for its ability to increase the anti-leak effect of anti-VEGF agents (ClinicalTrials.gov Identifier: NCT02712008). Aerpio AKB-9778 is a Tie-2 activating agent that effectively blocks vascular leak and pathologic angiogenesis in multiple disease conditions, and this agent is also being investigated for the treatment of DME (ClinicalTrials.gov Identifier: NCT02050828).

Besides new anti-angiogenic/anti-leak agents being developed, new delivery systems could potentially be developed. Slow-release anti-VEGF implants are being investigated for use in neovascular age-related macular degeneration, however to our knowledge, no devices are currently in any phase study for DME in the US.

As mentioned above, macular laser is still being investigated to determine the role of laser in DME. TREX-DME has reported 1-year data, and 2-year data will be available soon. Similarly, investigators are looking at the role of
micropulsed laser on the treatment burden of anti-VEGF in the Micropulsed Laser in Association With Anti-VEGF for the Treatment of Macular Edema in Diabetic Patients (LAMED) study (ClinicalTrials.gov Identifier: NCT02650050).

Many advances in treating DME have been made over the past decades and it is imperative that this area of research remains well funded, as diabetic eye disease is the leading cause of blindness in the working age individual. Anti-VEGF therapy remains first-line, however, it is necessary for any physician treating DME to have other options in their armamentarium. There are several clinical trials investigating a number of treatment options, and it is likely that a combination of treatments will provide the best balance of safety, efficacy, cost, and treatment burden.


Review Retina